



NDA 19-962/S-036

AstraZeneca
Attention: Paula Clark
1800 Concord Pike
P.O. Box 8355
Wilmington, DE 19803-8355

SUPPLEMENT APPROVAL

Dear Ms. Clark:

Please refer to your supplemental new drug application (NDA) dated December 20, 2007 submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for metoprolol succinate extended release 25, 50, 100, and 200 mg Tablets.

This supplemental new drug application provides for the following revision to the package insert:

In the **HOW SUPPLIED** section of the PI, the following sentence has been changed

FROM

Tablets containing metoprolol succinate equivalent to the indicated weight of metoprolol tartrate, USP, are white, biconvex, and film-coated.

TO

Tablets containing metoprolol succinate equivalent to the indicated weight of metoprolol tartrate, USP, are white, biconvex, film-coated and scored.

We have completed our review of this application, and it is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon electronic labeling text. We will transmit the SPL version of the labeling submitted on December 20, 2007 to the National Library of Medicine for public dissemination.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

Marketing the product with labeling that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Dan Brum, Pharm.D., Regulatory Project Manager, at (301)796-0578.

Sincerely,

{See appended electronic signature page}

Norman Stockbridge, M.D., Ph.D.
Director
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

cc: Enclosed Labeling Text

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Norman Stockbridge
2/15/2008 01:57:24 PM